Literature DB >> 17331884

Progress in targeting bacterial transcription.

Philippe Villain-Guillot1, Lionel Bastide, Maxime Gualtieri, Jean-Paul Leonetti.   

Abstract

The bacterial RNA polymerase (RNAP) is an essential enzyme that is responsible for making RNA from a DNA template and is targeted by several antibiotics. Rifampicin was the first of such antibiotics to be described and is one of the most efficient anti-tuberculosis drugs in use. In the past five years, structural studies of bacterial RNAP and the resolution of several complexes of drugs bound to RNAP subunits have revealed molecular details of the drug-binding sites and the mechanism of drug action. This knowledge opens avenues for the development of antibiotics. Here these drugs are reviewed, together with their mechanisms and their potential interest for therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17331884     DOI: 10.1016/j.drudis.2007.01.005

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  24 in total

Review 1.  Essential biological processes of an emerging pathogen: DNA replication, transcription, and cell division in Acinetobacter spp.

Authors:  Andrew Robinson; Anthony J Brzoska; Kylie M Turner; Ryan Withers; Elizabeth J Harry; Peter J Lewis; Nicholas E Dixon
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

2.  The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site.

Authors:  Audrey Tupin; Maxime Gualtieri; Jean-Paul Leonetti; Konstantin Brodolin
Journal:  EMBO J       Date:  2010-06-18       Impact factor: 11.598

Review 3.  Bacterial Transcription as a Target for Antibacterial Drug Development.

Authors:  Cong Ma; Xiao Yang; Peter J Lewis
Journal:  Microbiol Mol Biol Rev       Date:  2016-01-13       Impact factor: 11.056

4.  Identifying chelators for metalloprotein inhibitors using a fragment-based approach.

Authors:  Jennifer A Jacobsen; Jessica L Fullagar; Melissa T Miller; Seth M Cohen
Journal:  J Med Chem       Date:  2010-12-28       Impact factor: 7.446

5.  New insights into the bacterial RNA polymerase inhibitor CBR703 as a starting point for optimization as an anti-infective agent.

Authors:  Weixing Zhu; Jörg Haupenthal; Matthias Groh; Michelle Fountain; Rolf W Hartmann
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

6.  Evaluation of Bacterial RNA Polymerase Inhibitors in a Staphylococcus aureus-Based Wound Infection Model in SKH1 Mice.

Authors:  Jörg Haupenthal; Yannik Kautz; Walid A M Elgaher; Linda Pätzold; Teresa Röhrig; Matthias W Laschke; Thomas Tschernig; Anna K H Hirsch; Vadim Molodtsov; Katsuhiko S Murakami; Rolf W Hartmann; Markus Bischoff
Journal:  ACS Infect Dis       Date:  2020-09-21       Impact factor: 5.084

7.  Mechanism of transcription initiation at an activator-dependent promoter defined by single-molecule observation.

Authors:  Larry J Friedman; Jeff Gelles
Journal:  Cell       Date:  2012-02-17       Impact factor: 41.582

8.  The role of polymorphisms in the spliced leader addition domain in determining promoter activity in Brugia malayi.

Authors:  Michelle Bailey; Chitra Chauhan; Canhui Liu; Thomas R Unnasch
Journal:  Mol Biochem Parasitol       Date:  2010-11-25       Impact factor: 1.759

9.  rRNA (rrn) operon-engineered Bacillus subtilis as a feasible test organism for antibiotic discovery.

Authors:  Yukinori Tanaka; Hideaki Nanamiya; Koichi Yano; Koji Kakugawa; Fujio Kawamura; Kozo Ochi
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  Inhibition of transcription in Staphylococcus aureus by a primary sigma factor-binding polypeptide from phage G1.

Authors:  Mohammed Dehbi; Gregory Moeck; Francis F Arhin; Pascale Bauda; Dominique Bergeron; Tony Kwan; Jing Liu; John McCarty; Michael Dubow; Jerry Pelletier
Journal:  J Bacteriol       Date:  2009-04-17       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.